[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340823-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340823-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-transcriptional-regulation-with-a-cdk9-inhibitor-suppresses-growth-of-endocrine-and-palbociclib-resistant-erth-breast-cancers-abstract","Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine-and Palbociclib-Resistant ERþ Breast Cancers - Abstract","","Endocrine therapy combined with CDK4/6 inhibitors like palbociclib is effective for estrogen receptor–positive (ERþ) breast cancer, but many patients relapse with therapy-resistant disease. This study used multiple resistant cell line models for 2D and 3D inhibitor screening and confirmed pro-proliferative pathways (PI3K–AKT–mTOR). The screens identified transcription-associated CDK9 as a common hit, and AZD4573 synergized with palbociclib in both settings, producing tumor regression in xenografts with added fulvestrant.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-transcriptional-regulation-with-a-cdk9-inhibitor-suppresses-growth-of-endocrine-and-palbociclib-resistant-erth-breast-cancers-abstract/340823/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-transcriptional-regulation-with-a-cdk9-inhibitor-suppresses-growth-of-endocrine-and-palbociclib-resistant-erth-breast-cancers-abstract/340823.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in ERþ breast cancer treatment?","Question",{"text":63,"@type":64},"The study addresses endocrine therapy resistance, where many ERþ patients relapse despite treatment with CDK4/6 inhibitors such as palbociclib.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the inhibitor screening performed?",{"text":68,"@type":64},"Multiple resistant disease models were screened using both 2D and 3D-based inhibitor screening approaches.",{"name":70,"@type":61,"acceptedAnswer":71},"What role did CDK9 play and what was the therapeutic outcome?",{"text":72,"@type":64},"The study identified transcription-associated CDK9 as a common hit in ERþ resistant models, and the CDK9 inhibitor AZD4573 acted synergistically with palbociclib, with additional regression observed in xenograft models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340823,1791276302,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Targeting Transcriptional Regulation with a CDK9  \nInhibitor Suppresses Growth of Endocrine-and  \nPalbociclib-Resistant ERþ Breast Cancers  \nArany Soosainathan1, Marjan Iravani1, Rania El-Botty2, John Alexander1, Laura Sourd2, Ludivine Morisset2, Pierre Painsec2, Rebecca Orha1, Joanna Nikitorowicz-Buniak1, Sunil Pancholi1, Syed Haider1,  \nMitch Dowsett1,3, Elisabetta Marangoni2, Lesley-Ann Martin1, and Clare M. Isacke1  \nABSTRACT  \n◥  \nThe combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an effective and well-tolerated treatment for estrogen receptor–positive (ERþ) breast cancer, yet many patients relapse with therapy-resistant disease. Determining the mechanisms underlying endocrine therapy resistance is limited by the lack of ability to fully recapitulate inter- and intratumor heterogeneity in vitro and of availability of tumor samples from women with disease progression or relapse. In this study, multiple cell line models of resistant disease were used for both two-dimensional (2D)– and three-dimensional (3D)–based inhibitor screening. The screens conﬁrmed the previously reported role of pro-proliferative pathways, such as PI3K–AKT–mTOR, in endocrine therapy resistance and additionally identiﬁed the transcription-associated cyclin-dependent kinase CDK9 as a common hit in ERþ cell lines and patient-derived organoids modeling endocrine therapy–resistant disease in both the palbociclib-sensitive and palbociclib-resistant settings. The CDK9 inhibitor, AZD4573, currently in clinical trials for hematologic  \nmalignancies, acted synergistically with palbociclib in these ERþ in vitro 2D and 3D models. In addition, in two independent endocrine- and palbociclib-resistance patient-derived xenografts, treatment with AZD4573 in combination with palbociclib and fulvestrant resulted in tumor regression. Tumor transcriptional proﬁling identiﬁed a set of transcriptional and cell-cycle regulators differentially downregulated only in combination-treated tumors. Together, these ﬁndings identify a clinically tractable combination strategy for overcoming resistance to endocrine therapy and CDK4/6 inhibitors in breast cancer and provide insight into the potential mechanism of drug efﬁcacy in targeting treatment-resistant disease.  \nSigniﬁcance: Targeting transcription-associated CDK9 synergizes with CDK4/6 inhibitor to drive tumor regression in multiple models of endocrine-and palbociclib-resistant ERþ breast cancer, which could address the challenge of overcoming resistance inpatients.  \nIntroduction  \nApproximately80%ofbreast cancers are estrogen receptor–positive (ERþ) at diagnosis, with most patients receiving adjuvant endocrine therapy. Unfortunately, endocrine therapy resistance remains a signiﬁcant clinical problem with 13%–41% ERþ breast cancers relapsing following adjuvant endocrine therapy (1) . The major mechanismsidentiﬁed in driving resistance are (i) acquisition of mutations in the estrogen receptor (ESR1) resulting in ligand-independent ER signaling, and (ii) rewiring of the cross-talk pathways between ER and growth factor receptor signaling resulting in ER activation in the absence of estrogen (E2) and/or enhanced growth factor signaling via Ras–Raf–MAPK or PI3K–AKT–mTOR converging on cyclin D to promote cell-cycle progression(2). Targeting the cell cycle with cyclin-  \n1The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom. 2Translational Research Department, Institut Curie, Paris, France. 3Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, United Kingdom.  \nCorresponding Authors: Clare M. Isacke, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, [United Kingdom. E-mail: clare.isacke@icr.ac.uk](United Kingdom. E-mail: clare.isacke@icr.ac.uk); and Lesly-Ann Martin, [lesley-ann@cytetech.com](lesley-ann@cytetech.com)  \n[Cancer Res 2024](Cancer Res 2024);[8","cbCaibcQj2ykqlCv","https://ap.wps.com/l/cbCaibcQj2ykqlCv","pdf",1964929,"English","# Abstract\n# Introduction\n# Materials and Methods\n## Cell culture\n## Drugs","[{\"question\":\"What problem does the study address in ERþ breast cancer treatment?\",\"answer\":\"The study addresses endocrine therapy resistance, where many ERþ patients relapse despite treatment with CDK4/6 inhibitors such as palbociclib.\"},{\"question\":\"How was the inhibitor screening performed?\",\"answer\":\"Multiple resistant disease models were screened using both 2D and 3D-based inhibitor screening approaches.\"},{\"question\":\"What role did CDK9 play and what was the therapeutic outcome?\",\"answer\":\"The study identified transcription-associated CDK9 as a common hit in ERþ resistant models, and the CDK9 inhibitor AZD4573 acted synergistically with palbociclib, with additional regression observed in xenograft models.\"}]","Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine-and Palbociclib-Resistant ERþ Breast Cancers - Abstract | PDF",1790039048,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6fb2106f6281b78ffd39eb599d018773.webp",983,1286,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31ed229fd2ee50b3ace42edae7a28157.webp",982,1285,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a39970cb0f9df0581c25902cfb3db72b.webp",981,1283,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/778eed0af1cb2e370fbf656cae8cff2f.webp",980,1282]